AMRN topline Reduce-It results are expected Q3/18 Next earnings release will be around May 2. will have plenty of cash when Reduce-It is read out. Vascepa YOY growth is slowing. 2018 may get a boost if Vascepa continues to get approval in the countries of the middle east Reduce-It resuls will have a huge impact on the stock.